We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+17.58%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$2.97B
AUM Growth
+$703M
Cap. Flow
+$803M
Cap. Flow %
27.04%
Top 10 Hldgs %
34.36%
Holding
350
New
119
Increased
64
Reduced
60
Closed
59

Top Buys

Rank Stock Value
1
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$25.3M
2
LLY icon
Eli Lilly
LLY
+$24.5M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$18.4M
4
XFOR icon
X4 Pharmaceuticals
XFOR
+$15.7M
5
MGNX icon
MacroGenics
MGNX
+$12.2M

Top Sells

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$21.4M
2
KALV
KalVista Pharmaceuticals
KALV
+$20.2M
3
BMY icon
Bristol-Myers Squibb
BMY
+$17.9M
4
CLDX icon
Celldex Therapeutics
CLDX
+$17.7M
5
PRTA icon
Prothena Corp
PRTA
+$14.1M

Sector Composition

Rank Sector Weight
1 Healthcare 22.28%
2 Consumer Staples 0.05%
3 Financials 0.03%
4 Industrials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CCXI
26
PUT
DELISTED
ChemoCentryx, Inc.
CCXI
$26.2M 0.88%
512,000
+60,300
+13% +$3.63M
GWPH
27
PUT
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$25.8M 0.87%
119,100
+100,000
+524% +$18.8M
BHC icon
28
CALL
Bausch Health
BHC
$2.25B
$25.4M 0.85%
+800,000
New +$23.5M
SMH icon
29
PUT
VanEck Semiconductor ETF
SMH
$65B
$24.4M 0.82%
+200,000
New +$23.7M
LLY icon
30
Eli Lilly
LLY
$1.03T
$23.4M 0.79%
+125,000
New +$24.5M
XFOR icon
31
X4 Pharmaceuticals
XFOR
$377M
$22.5M 0.76%
87,166
+59,619
+216% +$15.7M
TCON
32
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$22.4M 0.75%
135,842
– –
IGMS
33
PUT
DELISTED
IGM Biosciences
IGMS
$19.2M 0.65%
250,000
– –
SAGE
34
PUT
DELISTED
Sage Therapeutics
SAGE
$18.7M 0.63%
+250,000
New +$20.5M
TVRD
35
CALL
Tvardi Therapeutics
TVRD
$19.7M
$18.4M 0.62%
23,517
+15,136
+181% +$10.4M
UTHR icon
36
CALL
United Therapeutics
UTHR
$26.2B
$17.6M 0.59%
105,000
+35,700
+52% +$5.95M
AZN icon
37
CALL
AstraZeneca
AZN
$266B
$17.4M 0.59%
175,000
– –
ZGNX
38
CALL
DELISTED
Zogenix, Inc.
ZGNX
$16.6M 0.56%
850,000
-17,400
-2% -$357K
JAZZ icon
39
CALL
Jazz Pharmaceuticals
JAZZ
$16.2B
$16.4M 0.55%
+100,000
New +$16.5M
INCY icon
40
CALL
Incyte
INCY
$24.9B
$16.3M 0.55%
+200,000
New +$17.1M
MRTX
41
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$16.2M 0.54%
94,500
+44,500
+89% +$8.81M
MCRB icon
42
CALL
Seres Therapeutics
MCRB
$46.3M
$16.1M 0.54%
39,000
+21,945
+129% +$10.1M
MGNX icon
43
MacroGenics
MGNX
$240M
$15.9M 0.54%
+500,469
New +$12.2M
LKFT
44
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
$15.5M 0.52%
+200,000
New +$18.4M
CMRX
45
DELISTED
Chimerix, Inc.
CMRX
$15.4M 0.52%
1,597,514
+365,001
+30% +$3.35M
BA icon
46
CALL
Boeing
BA
$175B
$15.3M 0.51%
+60,000
New +$13.3M
ACAD icon
47
PUT
Acadia Pharmaceuticals
ACAD
$4.55B
$14.9M 0.5%
+578,300
New +$25.5M
TWST icon
48
PUT
Twist Bioscience
TWST
$5.69B
$14.9M 0.5%
+120,000
New +$18.2M
CRIS icon
49
Curis
CRIS
$9.67M
$13.8M 0.47%
3,051
-887
-23% -$3.71M
MRNA icon
50
CALL
Moderna
MRNA
$23B
$13.1M 0.44%
+100,000
New +$14.5M
1
2
3 4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q1 2021 Portfolio in Review

As of Q1 2021, Ikarian Capital held 350 positions worth $2.97B, up 31% from $2.27B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Ikarian Capital deployed $803M of net new capital in Q1 2021, opening 119 new positions and adding to 64 existing holdings. Its largest new stake was Odonate Therapeutics, Inc. Common Stock: 1,336,412 shares worth $4.57M.

By sector, the portfolio is most concentrated in Healthcare at 22% of assets, down from 24% a quarter earlier, followed by Consumer Staples and Financials.

On the sell side, the largest reduction was Morphic Holding, Inc. Common Stock, an estimated $21.4M trimmed.

  • Ikarian Capital's largest Q1 2021 buy was Odonate Therapeutics, Inc. Common Stock: 1,336,412 shares worth $4.57M.
  • Ikarian Capital added most to X4 Pharmaceuticals in Q1 2021, an estimated $15.7M increase.
  • Ikarian Capital's biggest Q1 2021 reduction was Morphic Holding, Inc. Common Stock, cutting an estimated $21.4M.
  • Ikarian Capital fully exited Bristol-Myers Squibb in Q1 2021, selling an estimated $17.9M.
  • Ikarian Capital's ten largest holdings make up 34% of its $2.97B portfolio in Q1 2021.
  • Ikarian Capital opened 119 new positions and closed 59 in Q1 2021.
  • Ikarian Capital's portfolio value rose 31% quarter-over-quarter to $2.97B.

Based on Ikarian Capital's 13F filing for Q1 2021, filed 17 May 2021.